Vertaling van "patients with non-valvular atrial fibrillation " (Frans → Nederlands) :

Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: anti-thrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Search Date February 2009. [http ...]
Aguilar MI, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.

van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-40. de Denus S, Sanoski CA, Carlsson J et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis.
de Denus S, Sanoski CA, Carlsson J et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow up.

For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several
For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several randomized trials.1 Effective strategies for the secondary prevention of stroke include

randomized trials.1 Effective strategies for the secondary prevention of stroke include treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1). 1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1). 2, 3
treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1).1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1).2, 3

Hylek EM, Evans-Molina C, Shea C, Henault LE et Regan S: Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
Hylek EM, Evans-Molina C, Shea C, Henault LE en Regan S: Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.

Garcia D et Hylek E: Stroke prevention in elderly patients with atrial fibrillation.
Garcia D en Hylek E: Stroke prevention in elderly patients with atrial fibrillation.

D’après Camm AJ et Savelieva I. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.
Naar Camm AJ en Savelieva I. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.

Prévention de l'accident vasculaire cérébral (AVC) et de l'embolie systémique (ES) chez les patients adultes présentant une fibrillation atriale non valvulaire associée à un ou plusieurs des facteurs de risque suivants :
Preventie van cerebrovasculair accident (CVA) en systemische embolie bij volwassen patiënten met nonvalvulair atriumfibrilleren met één of meer van de volgende risicofactoren: